{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T06:52:59Z","timestamp":1653029579488},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"14","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>A case of invasive fungal infections (IFIs) with subtherapeutic posaconazole prophylaxis in a gastric bypass patient following hematopoietic stem cell transplantation (HSCT) is reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>A 52-year-old malnourished male with a medical history of Roux-en-Y gastric bypass for obesity developed acute myelogenous leukemia and underwent allogeneic HSCT approximately 17 months later. He was admitted 1 month after HSCT for failure to thrive and initiated on parenteral nutrition due to worsening diarrhea and suspected gastrointestinal graft-versus-host disease (GI GVHD). During admission, the patient was continued on daily oral posaconazole for antifungal prophylaxis and was found to have subtherapeutic posaconazole and deficient vitamin levels, likely secondary to his gastrojejunostomy and increased gastric transit time. The oral posaconazole was altered to twice-daily dosing in an effort to increase serum drug levels and prevent IFIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients with a history of gastric bypass are at increased risk for malabsorption of oral posaconazole and nutrients, especially following HSCT with suspected GI GVHD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxab164","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T21:34:07Z","timestamp":1619127247000},"page":"1282-1286","source":"Crossref","is-referenced-by-count":1,"title":["Subtherapeutic posaconazole prophylaxis in a gastric bypass patient following hematopoietic stem cell transplantation"],"prefix":"10.1093","volume":"78","author":[{"given":"Emily A","family":"Highsmith","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vi P","family":"Doan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd W","family":"Canada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"key":"2021071005390484900_CIT0001","volume-title":"Estimate of bariatric surgery numbers, 2011\u20132018","author":"American Society for Metabolic and Bariatric Surgery"},{"issue":"9","key":"2021071005390484900_CIT0002","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.bbmt.2017.05.035","article-title":"Current use and trends in hematopoietic cell transplantation in the United States","volume":"23","author":"D\u2019Souza","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2021071005390484900_CIT0003","doi-asserted-by":"crossref","first-page":"O1","DOI":"10.1002\/oby.22719","article-title":"Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures\u20142019 update: cosponsored by American Association of Clinical Endocrinologists\/American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists","volume":"28","author":"Mechanick","year":"2020","journal-title":"Obesity (Silver Spring)."},{"issue":"5","key":"2021071005390484900_CIT0004","doi-asserted-by":"crossref","first-page":"e12988","DOI":"10.1111\/obr.12988","article-title":"Pharmacokinetic changes post-bariatric surgery: a scoping review","volume":"21","author":"McLachlan","year":"2020","journal-title":"Obes Rev."},{"key":"2021071005390484900_CIT0005","volume-title":"Noxafil (posaconazole). Package insert","year":"2018"},{"issue":"4","key":"2021071005390484900_CIT0006","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.2010.03680.x","article-title":"Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview","volume":"70","author":"Lipp","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"2021071005390484900_CIT0007","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1517\/17425255.2012.722757","article-title":"The effects of gastric bypass surgery on drug absorption and pharmacokinetics","volume":"8","author":"Brocks","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2021071005390484900_CIT0008","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12281-016-0255-4","article-title":"Therapeutic drug monitoring of posaconazole: an update","volume":"10","author":"Dekkers","year":"2016","journal-title":"Curr Fungal Infect Rep"},{"key":"2021071005390484900_CIT0009","first-page":"1","article-title":"Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections","volume":"8","author":"Wiederhold","year":"2015","journal-title":"Clin Pharmacol."},{"issue":"8","key":"2021071005390484900_CIT0010","doi-asserted-by":"crossref","first-page":"e00188-17","DOI":"10.1128\/AAC.00188-17","article-title":"Real-life assessment of the safety and effectiveness of the new tablet and intravenous formulations of posaconazole in the prophylaxis of invasive fungal infections via analysis of 343 courses","volume":"61","author":"Tverdek","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"2021071005390484900_CIT0011","doi-asserted-by":"crossref","first-page":"e02655-17","DOI":"10.1128\/AAC.02655-17","article-title":"Antifungal prophylaxis with posaconazole delayed-release tablet and oral suspension in a real-life setting: plasma levels, efficacy, and tolerability","volume":"62","author":"Lenczuk","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"2021071005390484900_CIT0012","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/1078155216673228","article-title":"Failure to achieve therapeutic levels with high-dose posaconazole tablets potentially due to enhanced clearance","volume":"24","author":"Maleki","year":"2018","journal-title":"J Oncol Pharm Pract."},{"issue":"5","key":"2021071005390484900_CIT0013","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/bcp.13054","article-title":"Drug disposition before and after gastric bypass: fenofibrate and posaconazole","volume":"82","author":"Gesquiere","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"22","key":"2021071005390484900_CIT0014","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease\u2014biologic process, prevention, and therapy","volume":"377","author":"Zesier","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"2021071005390484900_CIT0015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrgastro.2017.126","article-title":"Acute graft-versus-host disease of the gut: considerations for the gastroenterologist","volume":"14","author":"Naymagon","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"2021071005390484900_CIT0016","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1093\/jac\/dkx228","article-title":"Risk factors for subtherapeutic levels of posaconazole tablet","volume":"2017","author":"Tang","journal-title":"J Antimicrob Chemother."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxab164\/37248843\/zxab164.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/14\/1282\/38891801\/zxab164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/14\/1282\/38891801\/zxab164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T08:40:37Z","timestamp":1625906437000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/78\/14\/1282\/6245082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":16,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2021,4,22]]},"published-print":{"date-parts":[[2021,7,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxab164","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,15]]},"published":{"date-parts":[[2021,4,22]]}}}